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Abstract: The Amaryllidaceae family has proven to be a rich source of active compounds, which
are characterized by unique skeleton arrangements and a broad spectrum of biological activities.
The aim of this work was to perform the first detailed study of the alkaloid constituents of Hippeastrum
reticulatum (Amaryllidaceae) and to determine the anti-parasitological and cholinesterase (AChE
and BuChE) inhibitory activities of the epimers (6α-hydroxymaritidine and 6β-hydroxymaritidine).
Twelve alkaloids were identified in H. reticulatum: eight known alkaloids by GC-MS and four
unknown (6α-hydroxymaritidine, 6β-hydroxymaritidine, reticulinine and isoreticulinine) by NMR.
The epimer mixture (6α-hydroxymaritidine and 6β-hydroxymaritidine) showed low activity against
all protozoan parasites tested and weak AChE-inhibitory activity. Finally, a molecular docking
analysis of AChE and BuChE proteins showed that isoreticulinine may be classified as a potential
inhibitory molecule since it can be stabilized in the active site through hydrogen bonds, pi-pi stacking
and hydrophobic interactions.
Keywords: 6α-hydroxymaritidine; 6β-hydroxymaritidine; reticulinine; isoreticulinine; Hippeastrum
reticulatum
1. Introduction
Natural products offer a wealth of bio-structural information that can be used to guide drug
discovery and molecular design projects [1]. Plants have played a huge role in traditional medicine,
and plant screening has become an important tool in drug discovery for pharmaceutical companies
and university institutes [2]. Alkaloids are plant secondary metabolites that are usually low in nitrogen
but high in oxygen [3]. Their three-dimensional complexity and interesting ring systems are of great
interest for drug development [3–5].
The Amaryllidaceae, a plant family in the monocot order Asparagales, is composed of three
subfamilies: Amaryllidoideae, Agapanthoideae and Allioideae [6,7]. The Amaryllidoideae include
about 80 genera [8] that are mainly distributed in tropical and subtropical regions, but also in temperate
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zones [9]. A particular feature of plants of the Amaryllidoideae subfamily is their content of an
exclusive, numerous and still expanding group of alkaloids, known as Amaryllidaceae alkaloids. These
compounds are characterized by unique skeleton arrangements and a broad spectrum of biological
activities [10]. Galanthamine is the most important Amaryllidaceae alkaloid, having received FDA
approval in 2001 for the clinical management of mild to moderate Alzheimer’s disease (AD) [11].
Over 47 million people worldwide were living with dementia in 2016, a figure expected to increase
to 131 million by 2050 [12]. The most common symptom of AD is a deterioration of memory and other
cognitive domains, leading to death within 3 to 9 years after diagnosis [13]. Multiple factors have been
implicated in AD pathology, including a reduced cholinergic neurotransmission level, oxidative stress
and aggregated amyloid-β-peptide (Aβ) [14].
Another global health challenge is tackling the neglected tropical diseases (NTDs), a diverse
group of communicable diseases that prevail in tropical and subtropical conditions and affect more
than a billion people [15]. The World Health Organization (WHO) lists 17 NTDs, including Chagas
disease, human African trypanosomiasis (sleeping sickness) and leishmaniosis. Alongside malaria,
these diseases are highly feared in affected populations, where poverty limits access to prevention
and treatment interventions [15]. One of the main reasons why these diseases are “neglected” is that
there is little incentive for the pharmaceutical industry to invest in developing drugs for a patient
population that cannot afford them [16]. Consequently, much of the research on effective treatment of
these diseases is carried out in academic laboratories with limited financial, personnel, and technical
resources [16].
The Hippeastrum Herb. is a genus (Amaryllidaceae) native to South America and comprises
approximately 60 species [17], about 30 of which are found in Brazil; the majority are endemic
and poorly studied [18]. This genus has been traditionally used to cure piles, tumors and various
inflammatory disorders such as asthma [19]. Physiological activities reported for plants of this
genus include psychopharmacological [20], against Trichomonas vaginalis [21] and cytotoxicity [22,23].
The species H. reticulatum is widely used as an ornamental plant due to its colorful flowers ranging
from light pink to dark purple [24]. In recent years, some studies have been published about its
primary metabolites, pigment constituents (anthocyanins), botanical characterization, karyotypes and
phylogenesis [9,24–26].
The aim of this work was to perform the first study of the alkaloid profile and biological
activities of Hippeastrum reticulatum. Four new alkaloids were isolated and chemically characterized
by spectroscopic methods and eight known alkaloids were identified by gas chromatography-mass
spectrometry (GC-MS). Anti-parasitological and cholinesterase—acetylcholinesterase (AChE) and
butyrylcholinesterase (BuChE)—inhibitory activities of the epimers (compounds 1 and 2, Figure 1) are
described. Molecular docking studies were also carried out to investigate the affinity of the four new
compounds for the active sites of AChE and BuChE based on intermolecular features such as hydrogen
bonds, pi-pi stacking and hydrophobic interactions. Unfortunately, it was not possible to determine the
biological activities of the isomers (compounds 3 and 4, Figure 1) due to a lack of samples.
2. Results and Discussion
2.1. Alkaloid Identification by GC-MS
The MeOH extracts of H. reticulatum plants were fractioned following the sequence described
in the Experimental section. The fractions were analyzed and the structural types of the alkaloids
from this species were identified by comparing their GC-MS spectra and Kovats Retention Index
(RI) values with those of authentic Amaryllidaceae alkaloids previously isolated and identified by
spectrometric methods (NMR, UV, CD, IR, MS) in our laboratory, by the NIST 05 Database or by
literature data (Table 1). Eight known alkaloids were identified by GC-MS using our Amaryllidaceae
alkaloid library (Figure 1) and four new alkaloids (1–4) were isolated and chemically characterized by
spectroscopic methods.
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Table 1. Alkaloids identified in H. reticulatum by GC-MS.
alkaloid RI M+ MS
galanthamine (11) 2410.8 287 (84) 288 (20), 286 (100), 270 (15), 244 (27),230 (15), 216 (37), 174 (32), 159 (11), 115 (16)
sanguinine (12) 2430.5 273 (100) 274 (16), 272 (77), 256 (23), 202 (31), 197 (15),165 (14) 160 (45), 152 (15), 115 (19)
6β- and 6α-hydroxymaritidine (1)
and (2) 2495.5 303 (20)
286 (9), 274 (12), 260 (21), 259 (100), 258 (12),
256 (20), 241 (30) 128 (16), 115 (20)
8-O-demethylmaritidine (6) 2522.4 273 (100) 274 (18), 230 (24), 203 (19), 202 (25), 201(89),189 (55), 175 (23), 115 (19), 56 (20)
maritidine (5) 2528.5 287 (100) 288 (20), 244 (35), 217 (20) 216 (25), 215 (95),203 (55), 189 (18), 128 (17), 115 (20)
11,12-dehydroanhydrolycorine (10) 2629.3 249 (59) 248 (100), 218 (1),190 (26), 163 (8), 137 (1),123 (5), 95 (13)
m/z 264 2693.6 265 (76) 264 (100), 248 (18), 220 (12), 191 (14),178 (18)
11-hydroxyvittatine (7) 2732.5 287 (5) 259 (16), 258 (100), 242 (9), 214 (9), 212 (8),211 (13), 186 (13), 181 (14), 128 (11)
lycorine (9) 2771.8 287 (18) 286 (10), 268 (19), 250 (16), 238 (7), 227 (78),226 (100), 211 (6), 147 (5), 119 (3)
isoreticulinine (4) 2829.1 333 (<1) 291 (37), 290 (100), 274 (11), 272 (6), 256 (5),228 (5), 147 (13)
reticulinine (3) 2133.4 333 (42) 332 (100), 316 (5) 290 (6), 272 (56), 256 (31),244 (14), 216 (14), 147 (26)
m/z 294 2950.3 295 (87) 294 (100), 278 (10), 264 (3), 250 (7), 235 (3),221 (5), 207 (3), 194 (5)
m/z 280 2978.6 281 (75) 280 (100), 264 (12), 250 (3), 236 (11), 219 (4),207 (4), 194 (8), 178 (4), 167 (3)
2-methoxypratosine (8) 3071.1 309 (100) 310 (20), 294 (18), 284 (7), 266 (24), 251 (14),236 (6), 164 (4), 152 (6)
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2.2. Structural Elucidation by NMR
2.2.1. 6β-Hydroxymaritidine (1) and 6α-hydroxymaritidine (2)
Compounds 1 and 2 were obtained together from an acetate leaf fraction and isolated as a mixture,
which was not separated by conventional chromatographic methods. The HRMS data of compounds 1
and 2 suggested the molecular formula C17H22NO4 for the parent ion [M + H]+ at m/z 304.1544 (calcd
304.1543). The absolute configuration of these epimers was determined by circular dichroism (CD).
The curve and shape were qualitatively similar to those of known haemanthamine-type alkaloids,
with the 5,10b-ethano bridge in an α-orientation, having a minimum of 250 nm and a maximum of
around 285 nm. The 1H-NMR data of compounds 1 and 2 (Table 2) were similar to the data published
for papyramine and 6-epi-papyramine [27] (Figure 2). The spectrum showed two singlets at δ 5.35
and 6.12 due to the benzylic H-6 proton for epimers 1 and 2, respectively. Two double doublets of the
olefinic protons at δ 5.98 and 6.02 were assignable to the H-2 protons of both epimers (compounds 1
and 2, respectively) due to their coupling with the H-1 doublets at 6.59 and 6.51 ppm, respectively.
The value of the H-2/H-3 coupling constant (J = 5.3 and 5.1 Hz, respectively) was in agreement with
a β-orientation of the hydroxyl group at C-3. The assignment of the aromatic protons was made on
the basis of the relative intensities of the signals of both epimers and the benzylic coupling between
H-6 and H-7, observed in the 2D COSY experiment. Two signals for the methoxy groups at δ 3.90
and 3.87 were observed, both of them integrating 4.3 protons (since epimers 1 and 2 were in a ratio
of 3:1). The protons H-4a and H-4ax showed a large coupling (J = 13.6 and 13.8 Hz, compound 1
and 2, respectively), due to their trans diaxial configuration. The NOESY contour between H-6α and
H-12endo allowed us to assign the β-orientation of the hydroxyl group in compound 1 (Figure 3).
The coupling between H-12exo and H-4α allowed us to establish the conformational orientation of
these protons in compound 2 (Figure 3). All the signals were confirmed by 2D-NMR.
Table 2. NMR data for compounds 1 and 2 (500 MHz for 1H and 125 Hz for 13C, CDCl3).
1 2
No. δC, type δH (J in Hz) δC, type δH (J in Hz)
1 130.7, d 6.59, d (10.0) 129.2, d 6.51, d (10.1)
2 127.9, d 5.98, dd (5.3 and 10.4) 128.4, d 6.02, dd (5.1 and 10.0)
3 63.2, d 4.32, m 62.1, d 4.37, m
4α 31.0, t 1.72, dt (4.0 and 13.7) 30.5, t 1.85, dt (4.0 and 13.4)
4β 31.0, t 2.14, dd (4.1 and 13.3) 30.5, t 2.29, dd (4.2 and 13.8)
4a 56.4, d 4.15, dd (4.1 and 13.6) 61.7, d 3.89, m
6a 125.2, s - 123.4, s -
6 88.8, d 5.35, s 86.6, d 6.12, s
7 111.8, d 6.89, s 110.7, d 7.03, s
8 148.0, s - 148.4, s -
9 148.9, s - 149.2, s -
10 105.3, d 6.83, s 105.1, d 6.78, s
10a 136.0, s - 133.7, s -
10b 44.2, s - 44.8, s -
11exo 39.9, t 2.03, m 39.8, t 2.03
11endo 39.9, t 2.03, m 39.8, t 2.03
12exo 47.4, t 3.37, ddd (3.8; 10.0 and 13.6) 41.2, t 3.19, ddd (3.5; 10.4 and 13.6)
12endo 47.4, t 2.87, ddd (6.5; 9.0 and 13.1) 41.2, t 3.94, m
OMe 56.1, q 3.90, s 56.1, q 3.90, s
OMe 55.9, q 3.87, s 55.9, q 3.87, s
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2.2.2. Reticulinine (3) and Isoreticulinine (4)
Compounds 3 and 4 were obtained from an acetate bulb fraction and isolated as a mixture due to
limited sample availability. The HRMS data of compounds 3 and 4 suggested the molecular formula
C17H22NO4 for the parent ion [M + H]+ at m/z 334.1651 (calcd 334.1649). The 1H-NMR data summarized
in Table 3 were similar to those reported for zephyranthine, 1,2-O-diacetylzephyranthine [28] and
sternbergine [29] and 1-O-acetylcaranine [30] (Figure 2). A correlation between the protons of the
methoxy group and H-10 in the 2D NOESY spectrum allowed us to assign this group at C-9 in both
compounds (Figure 4). The two double doublets at δ 3.11 (J = 5.9 and 10.4 Hz) and 3.22 (J = 5.9
and 10.7 Hz) were attributed to the H-4a position in compounds 3 and 4, respectively. The large
coupling constant supported a trans-fusion of the B/C rings in both structures. The location and axial
configuration of the radical group at C-1 in compounds 3 and 4, respectively, were deduced from COSY
and NOESY experiments (Figure 4). In compound 3, the low magnetic field location of the H-1 and H-2
protons (δ 6.01 and 4.15 ppm, respectively) in the 1H spectrum allowed us to determine the presence
of an acetyl group at C-1 and a hydroxyl group at C-2, respectively. Conversely, in compound 4,
the low magnetic field of the H-1 and H-2 protons (δ 4.77 and 5.12 ppm, respectively) indicated a
hydroxyl group at C-1 and an acetyl group at C-2, respectively. In these compounds, the equatorial
H-1 resonated as a triplet at δ 6.01 (J = 3.9 Hz) and 4.77 (J = 1.5 Hz), respectively, and was coupled to
H-10b and H-2 in the COSY spectrum, and to H-10 in the NOESY experiment (Figure 4). These data
and the large constant coupling between H-2 and H-3α in compounds 3 and 4 (J = 9.8 and 11.6 Hz,
respectively) allowed us to assign the equatorial configuration of the substituent at C-2. From the
HMBC spectrum, three bond correlations were observed for H-7 to C-9, H-10 to C-8, H-7 to C-10a and
H-10 to C-6a, enabling us to identify the resonances of the quaternary carbons C-8, C-9, C-6a and C-10a.
In addition, a three-bond coupling between the methoxy protons and C-9 confirmed the NOESY result
(Figure 4).
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No. δC, type δH (J in Hz) δC, type δH (J in Hz)
1 70.6 d 6.01, t (3.9) 66.9 d 4.77, t (1.5)
2 68.4 d 4.15, ddd (2.8; 7.1 and 9.8) 72.1 d 5.12, ddd (2.5; 5.4 and 11.6)
3α 25.8 t 2.02, m 26.8 t 2.23, ddd (6.2; 11.8 and 13.4)
3β 25.8 t 2.02, m 26.8 t 1.95, m
4 36.7 d 2.68, m 36.4 d 2.68, m
4a 58.0 d 3.11, dd (5.9 and 10.4) 57.4 d 3.22, dd (5.9 and 10.7)
6α 51.4 t 4.28, d (16.7) 51.6 t 4.29, d (16.4)
6β 51.4 t 3.73, d (16.7) 51.6 t 3.74, d (16.9)
6a 127.7 s - 127.7 s -
7 112.7 d 6.67, s 112.9 d 6.68, s
8 144.0 s - 144.0 s -
9 145.4 s - 145.4 s -
10 106.4 d 6.73, s 106.4 d 6.82, s
10a 126.7 s - 126.7 s -
10b 33.1 d 2.68, m 34.3 d 2.59, d (10.5)
11α 29.7 t 1.85, m 29.9 t 2.04, m
11β 29.7 t 1.77, m 29.9 t 1.85, m
12α 52.7 t 3.39, m 52.9 t 3.39, m
12β 52.7 t 2.81, m 52.9 t 2.81, m
OMe 56.0 q 3.82, s 56.1 q 3.89, s
MeCOO 172.2 q 2.06, s 170.4 q 2.16, s
MeCOO 21.1 q 2.06, s 21.3 q 2.16, s
2.3. Biological Activity
2.3.1. Antiprotozoal Activity
6β-Hydroxymaritidine (1) and 6α-hydroxymaritidine (2) were isolated as an epimer mixture,
which showed low activity agai st all protozoan parasit s tested (Table 4). However, this sample
also presente lo cytotoxicity (>100 µg mL−1), so it could b interesting to isolate the epimers and
nalyz their individual antiprotozoal activity. The quantity of reticulinine (3) and isoreticulinine (4)
was insufficient for an ntiprot z al study.
2.3.2. Acetylcholinesterase and Butyrylcholinesterase Inhibitory Activities
6β-Hydroxymaritidine (1) and 6α-hydroxymaritidine (2), isolated as an epimer mixture, were
tested for in vitro AChE- and BuChE-inhibitory activities. With galanthamine s a positive control,
the epimers exhibited weak AChE inhibition (IC50 90.43 ± 4.26 µM) and no BuChE inhibition
(IC50 > 600 µM), while galanthamine presented AChE and BuChE inhibition (IC50 1.56 ± 0.14 and
12.96 ± 0.65 µM, respectively). As described below in the molecular docking results, it would be of
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interest to check the cholinesterase inhibitory activities of reticulinine (3) and isoreticulinine (4), but
their low amounts precluded these assays.
Table 4. In vitro antiprotozoal and cytotoxic activities of 1 and 2. Values expressed in µg ml-1.
Parasite T. b. rhodesiense T. cruzi L. donovani P. falciparum Cytotoxicity
Stage Trypomastigotes Amastigotes Amastigotes IEF (intraerythrocytic)
Strain STIB 900(IC50 )
Tulahuen C4
(IC50 )
MHOM-ET-67/L82
(IC50 )
NF54
(IC50 )
L6
(IC50 )
melarsoprol 0.0010
benznidazole 1.080
miltefosine 0.091
chloroquine 0.002
podophyllotoxin 0.007
compounds 1 and 2 30.68 66.11 >100 32.86 >100
2.4. Molecular Docking
All the new structures obtained from H. reticulatum had their theoretical acetyl- and
butyrylcholinesterase inhibitory potential evaluated by molecular docking. The results of their binding
interactions and orientation patterns with the active site gorge of AChE and BuChE are represented in
Table 5.
Table 5. Estimated energies of reaction and inhibition constants for the new compounds in the active
sites of AChE and BuChE.
Alkaloids 1DX6 a (kcal mol−1) 4EY7 b (kcal mol−1) 4BDS c (kcal mol−1)
6β-hydroxymaritidine (1) −8.49 −9.44 −8.95
6α-hydroxymaritidine (2) −8.25 −8.75 −8.72
reticulinine (3) −8.88 −8.87 −8.10
isoreticulinine (4) −9.02 −9.80 −8.12
galanthamine (11) −9.36 −10.10 −8.74
a 1DX6: Torpedo californica Acetylcholinesterase; b 4EY7: Human Acetylcholinesterase; c 4BDS: Human
Butyrylcholinesterase.
The simulated molecular docking on the 1DX6 and 4EY7 structures showed that the alkaloid
isoreticulinine (4) theoretically has a higher inhibitory effect against AChE than reticulinine (3),
6β-hydroxymaritidine (1) and 6α-hydroxymaritidine (2), but lower than galanthamine by 0.34 and
0.30 kcal mol−1, respectively. The docking results obtained for isoreticulinine suggest that the presence
of a hydroxyl and an acetyl group at the C-1 and C-2 positions, respectively, theoretically improves
the AChE inhibition on the 1DX6 and 4EY7 structures in comparison with reticulinine. Structural
representations of the best conformation of the complexed active site of the TcAChE with galanthamine
and isoreticulinine (4) are depicted in Figure 5.
The molecular docking results reported in Table 5 are analyzed here in terms of different
interactions between the alkaloids and active site of the TcAChE protein: hydrogen bonds, pi-pi stacking
and anionic interactions. Regarding hydrogen bonding, galanthamine showed the highest stability
due to two strong interactions with the Glu199 and Ser200 residues, while the isoreticulinine
complex presented only one interaction with the Ser200 residue. Both these alkaloids have a
similar localization according to pi-pi stacking, interactions with Trp84, Phe330 and Asp72 residues,
and anionic stabilization. The hydrogen bond interaction of reticulinine (3) is as depicted in
Figure 5 for isoreticulinine (4), with a distance close to 1.9 A. The hydrogen bond interactions for
6β-hydroxymaritidine (1) and 6α-hydroxymaritidine (2) are similar, although anionic and pi-pi stacking
interactions suggest a different, more distant localization, in accordance with the binding free energies
reported in Table 5.
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The molecular simulation of 6β-hydroxymaritidine (1) on the 4BDS structure theoretically showed
more potent enzymatic inhibition against BuChE than 6α-hydroxymaritidine (2), isoreticulinine (4) and
reticulinine (3), and interestingly, it was higher than galanthamine by 0.21 kcal mol−1. These results
also indicate that 6α-hydroxymaritidine (2) theoretically has virtually the same inhibitory activity as
galanthamine toward BuChE, differing by only 0.02 kcal mol−1. Furthermore, the docking results
propose that the β-orientation of the hydroxyl group at the C-6 position in 6β-hydroxymaritidine
(1) could improve the butyrylcholinesterase inhibition on the 4BDS structure by 0.23 kcal mol−1
compared to the α-orientation of the hydroxyl group at the C-6 position in 6α-hydroxymaritidine (2).
Structural representations of the best conformation of the complexed active site of human BuChE with
6β-hydroxymaritidine (1) are presented in Figure 6.Molecules 2017, 22, 2191 9 of 15 
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In the case of BuChE, 4BDS in the PDB code, the crystallographic data show that tacrine,
a molecule for anti-Alzheimer’s drugs targeting acetyl- and butyryl-cholinesterase, is stabilized by
pi-pi stacking interactions between the aromatic rings and the Trp82 residue; additionally, this ligand
is stabilized by the presence of hydrophobic interactions with Trp430, Ala328 and His438. On the
other hand, similar to TcAChE, the active site shows the presence of two available residues available
for hydrogen bond interactions, Glu197 and Ser198. In terms of pi-pi stacking interactions, Figure 6
shows that 6β-hydroxymaritidine (1) is more stable than isoreticulinine (4). However, the localization
of 6β-hydroxymaritidine in the active site is not appropriate for forming hydrogen bonds with the
Glu197 and Ser198 residues. The results suggest that in an ideal BuChE inhibitor pi-pi stacking and
hydrogen bond interactions should be in equilibrium, and among the tested molecules isoreticulinine
was closest to this definition. In terms of hydrophobic interactions, all molecular docking analyses
reported similar interactions between the alkaloids and Trp430, Ala328 and His438 residues.
The theoretical results obtained by molecular docking for 6β-hydroxymaritidine (1) and
6α-hydroxymaritidine (2) BuChE inhibition are not in agreement with the experimental assays.
The difference between the BuChE structure used for the molecular docking (human) and experiments
(equine serum), as well as the inability of these compounds to arrive to the active site gorge of BuChE
may help understand the difference between the theoretical and practical results. Moreover, the use of
an epimer mixture in the assays could also have contributed to the discrepancy between the theoretical
and practical results.
According to the molecular interactions shown in the docking analysis, the isoreticulinine
alkaloid (4) may be catalogued as a potential inhibitory molecule based on its very good interaction
with the active site through strong hydrogen bonds in both of the proteins evaluated, AChE and
BuChE. Additionally, the position of isoreticulinine alkaloid (4) on the gorge of the active sites showed
that it can be stabilized by pi-pi stacking and hydrophobic interactions.
AChE is highly selective for ACh hydrolysis, while BuChE is able to metabolize different
substrates [31]. AChE activity in the brain of Alzheimer's disease patients tends to decrease, while
that of BuChE increases [32]. Consequently, the search for a structure able to simultaneously inhibit
both enzymes may provide a better therapeutic response for Alzheimer’s disease than AChE-selective
agents [33]. This information adds to the importance of the results obtained herein for isoreticulinine (4)
by molecular docking.
3. Materials and Methods
3.1. General Experimental Procedures
About 2 mg of each alkaloid extract were dissolved in 1000 µL of MeOH and/or CHCl3 and injected
directly into the GC-MS apparatus (Agilent Technologies 6890N coupled with MSD5975 inert XL, Santa
Clara, CA, USA) operating in the EI mode at 70 eV. A Sapiens-X5 MS column (30 m × 0.25 mm i.d., film
thickness 0.25 µm, Teknokroma, Barcelona, Spain) was used. The temperature gradient performed was
the following: 2 min at 100 ◦C, 100–180 ◦C at 15 ◦C min−1, 180–300 ◦C at 5 ◦C min−1 and 10 min hold at
300 ◦C. The injector and detector temperatures were 250 ◦C and 280 ◦C, respectively, and the flow-rate
of carrier gas (He) was 1 mL min−1. A split ratio of 1:10 was applied and the injection volume was 1 µL.
1H, 13C-NMR, COSY, NOESY, HSQC, and HMBC spectra were recorded on a Varian VNMRS
500 MHz (Palo Alto, CA, USA) and a Bruker 400 MHz Avance III (Billerica, MA, USA) equipped with
CryoProbe Prodigy, using CDCl3 as the solvent and TMS as the internal standard. Chemical shifts are
reported in units of δ (ppm) and coupling constants (J) expressed in Hz. CD, UV and IR spectra were
recorded on Jasco-J-810 (Easton, MD, USA), Dinko UV2310 (Barcelona, Spain) and Thermo Scientific
Nicolet iN10 MX spectrophotometers (Waltham, MA, USA), respectively. HR-ESI-MS spectra were
obtained on an LC/MSD-TOF (2006) mass spectrometer (Agilent technologies, Santa Clara, CA, USA).
Silica gel SDS chromagel 60 A CC (6–35 µm) (Carlo Erba Reagents, Val de Reuil, France) was used for
VLC, and silica gel 60 F254 (Merck, Darmstadt, Germany) for analytics and preparative TLC. Spots
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on chromatograms were detected under UV light (254 nm) (Spectroline, Westbury, NY, USA) and by
Dragendorff’s reagent stain.
3.2. Plant Material
Bulbs and leaves of Hippeastrum reticulatum Herb. were collected in Floresta Nacional de
Goytacazes (Espírito Santo, Brazil) in May 2015. The samples were authenticated by Dr Julie H.
A. Dutilh, Universidade de Campinas (UNICAMP, Campinas, Brazil). A specimen voucher (VIES
38724) has been deposited in the Herbarium VIES from Universidade Federal do Espírito Santo (UFES,
Vitória, Brazil).
3.3. Extraction and Isolation
Fresh bulbs (1.5 kg) and leaves (400 g) of H. reticulatum were collected and macerated with MeOH
(2 × 1.0 L) at room temperature for 4 days, the combined macerate filtered and the solvent evaporated
to dryness under reduced pressure. The bulb and leaf crude extracts (117.3 and 53.5 g, respectively)
were then acidified to pH 3 with diluted H2SO4 (2%, v/v). The neutral material was removed with
Et2O (10 × 150 mL) and then extracted with EtOAc (3 × 150 mL) to provide the acid EtOAc extracts
(0.60 and 0.44 g, respectively). The aqueous solutions were basified up to pH 9-10 with NH4OH (25%,
v/v) and extracted with n-Hex (16 × 150 mL) to give the n-Hex extracts (0.14 and 0.02 g, respectively),
which were followed by extraction with EtOAc (15 × 150 mL) to provide the EtOAc extracts (1.6 and
0.3 g, respectively) and finally extracted with EtOAc:MeOH (3:1, v/v) (4 × 150 mL) to provide the
EtOAc:MeOH extracts (2.10 and 1.56 g, respectively).
The extracts were subjected to a combination of chromatographic techniques, including vacuum
liquid chromatography (VLC) [34] and semi-preparative TLC. The general VLC procedure consisted of
the use of a silica gel 60 A (6–35 µm) column with a height of 4 cm and a variable diameter according
to the amount of sample (2.5 cm for 400–1000 mg; 1.5 cm for 150–400 mg). Alkaloids were eluted with
n-Hex containing increasing EtOAc concentrations, followed by neat EtOAc, which was gradually
enriched with MeOH (reaching a maximum concentration of 20%, v/v). Fractions of 10–15 mL were
collected, monitored by TLC (UV 254 nm, Dragendorff’s reagent [35,36]), and combined according
to their profiles. For semi-preparative TLC, silica gel 60F254 was used (20 cm × 20 cm × 0.25 mm)
together with different solvent mixtures depending on each particular sample (EtOAc:MeOH, 9:1, v/v
or EtOAc:MeOH, 8:2, v/v), always in an environment saturated with ammonia. Each known alkaloid
was identified by GC-MS and the four new alkaloids were structurally elucidated by NMR.
The EtOAc leaf extract (0.3 g) was subjected to a VLC column (2.5 cm × 4.0 cm), starting the
elution with 100% n-Hex, gradually increasing the polarity with EtOAc up to 100% EtOAc, and finally
increasing the MeOH percentage in the mixture up to a ratio of EtOAc:MeOH (80:20, v/v), similar
to the methodology used in Hippeastrum aulicum by Bessa and co-workers [37]. 580 fractions (10 mL
each) were collected, analyzed by TLC and grouped in nine fractions. Fraction 5 (72.8 mg), eluted with
EtOAc:MeOH (eluted with 95:05 until 90:10, v/v), was subjected to a semi-preparative TLC using 2
plates and a mobile phase consisting of EtOAc:MeOH (80:20, v/v) in an environment saturated with
ammonia, and 15.60 mg of the epimer mixture 1 and 2 was isolated.
Exclusion chromatography was carried out using a Sephadex LH-20 column (2.5 cm × 40 cm)
to clean and separate the alkaloids present in the EtOAc bulb extract (1.6 g). It was eluted with 100%
MeOH, producing 147 fractions, each one containing about 2 mL, which were monitored by TLC
and grouped in four fractions. Fraction 2 (801 mg) was chromatographed again in a Sephadex LH-20
in the same conditions, producing 120 sub-fractions, which were grouped in seven sub-fractions.
Sub-fraction 2 (10.2 mg) was subjected to a TLC plate, applying 3 runs over a mobile phase consisting
of EtOAc:MeOH (80:20, v/v) in an environment saturated with ammonia to obtain 1.09 mg of the
isomers 3 and 4.
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3.4. Characterization of Compounds
6β-Hydroxymaritidine (1) and 6α-hydroxymaritidine (2): Amorphous solid; [α]22D −11.22 (c 0.98, CHCl3);
UV (MeOH) λmax (log ε): 282.5 (3.64), 234.0 (3.92) nm; CD (MeOH, 20 ◦C) ∆ε250 −340, ∆ε284 +5938;
IR vmax cm−1 3341, 2958, 1609, 1512, 1464, 1406, 1268, 1246, 1222, 1192, 1141, 1113, 1043, 1017, 941, 866,
779, 746; 1H-NMR (CDCl3, 500 MHz) and 13C-NMR (CDCl3, 125 MHz) see Table 2; EIMS data shown
in Table 1; HREIMS of [M + H]+ at m/z 304.1544 (calcd 304.1543).
Reticulinine (3) and isoreticulinine (4): Amorphous solid; 1H-NMR (CDCl3, 400 MHz) and 13C-NMR
(CDCl3, 100 MHz) see Table 3; IR vmax cm−1 2852, 1732, 1571, 1513, 1452, 1375, 1240, 1114, 1047; EIMS
data shown in Table 1; [M + H]+ at m/z 334.1651 (calcd 334.1649).
3.5. Biological Activity
3.5.1. Antiprotozoal Activity
In vitro tests for the biological activity of the epimers 6β-hydroxymaritidine (1) and
6α-hydroxymaritidine (2) against Trypanosoma brucei rhodesiense (trypomastigotes forms, STIB 900
strain), Trypanosoma cruzi (amastigotes forms, Tulahuen C4 strain), Leishmania donovani (amastigotes
forms, MHOM-ET-67/L82 strain), and Plasmodium falciparum (intraerythrocytic forms, IEF, NF54 strain)
and a cytotoxicity test against the mammalian L6 cell line from rat skeletal myoblasts were carried
out at the Swiss Tropical and Public Health Institute (Swiss TPH, Basel, Switzerland) according to
established protocols as described by Orhan and co-workers [38]. The reference drugs used in these
assays were melarsoprol, benznidazole, miltefosine, chloroquine and podophyllotoxin, respectively.
3.5.2. Acetylcholinesterase and Butyrylcholinesterase Inhibitory Activities
Cholinesterase inhibitory activities were analyzed as by Ellman and co-workers [39] with some
modifications as by López and co-workers [40]. Fifty microliters of AChE or BuChE in phosphate
buffer (8 mM K2HPO4, 2.3 mM NaH2PO4, 0.15 NaCl, pH 7.5) and 50 µL of the sample dissolved
in the same buffer were added to the wells. The plates were incubated for 30 minutes at room
temperature before 100 µL of the substrate solution (0.1 M Na2HPO4, 0.5 M DTNB, and 0.6 mM ATCI
or 0.24 mM BTCI in Millipore water, pH 7.5) was added. The absorbance was read in a Labsystem
microplate reader (Thermo Electron Corporation, Vantaa, Finland) at 405 nm after 10 minutes. Enzyme
activity was calculated as a percentage compared to an assay using a buffer without any inhibitor.
The cholinesterase inhibitory data were analyzed with the software Microsoft Office Excel 2010.
The epimer concentrations used to calculate IC50 values were 10, 20, 40, 60, 80, 100 and 200 µg mL−1 in
both AChE and BuChE assays.
3.6. Molecular Docking
The molecular docking simulations for 6β-hydroxymaritidine (1), 6α-hydroxymaritidine (2),
reticulinine (3) and isoreticulinine (4) were performed to investigate the binding mode in the active site
of three different enzymes, Torpedo californica AChE (TcAChE), hBChE, and hAChE, proteins with PDB
codes 1DX6 [41], 4BDS [42], and 4EY7 [43], respectively. The 3D structures of the alkaloids were drawn
with the Chemcraft program [44] and then submitted to a geometrical optimization procedure using
PBE0 [45] /6-311+g* [46] level of theory with the Gaussian 09 program [47]. All optimized alkaloids
were confirmed as a minimum on the potential energy surface. The docking simulations for the set of
optimized ligands were performed using the AutoDock v.4.2 program [48].
AutoDock combines a rapid energy evaluation through precalculated grids of affinity potentials
with a variety of search algorithms to find suitable binding positions for a ligand on a given
macromolecule. To compare the results from the docking simulations, the water molecules, cofactors,
and ions were excluded from each X-ray crystallographic structure. Likewise, the polar hydrogen
atoms of the enzymes were added and the non-polar hydrogen atoms were merged. Finally, the
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enzyme was treated as a rigid body. The grid maps of interaction energy for various atom types with
each macromolecule were calculated by the auxiliary program AutoGrid choosing a grid box with
dimensions of 60 × 60 × 60 Å around the active site, which was sufficiently large to include the most
important residues of each enzyme. The docking searches for the best orientations of the ligands
binding to the active site of each protein were performed using the Lamarckian Genetic Algorithm,
(LGA) [49]. The LGA protocol applied a population size of 2000 individuals, while 2,500,000 energy
evaluations were used for the 50 LGA runs. The best conformations were chosen from the lowest
docked energy solutions in the cluster populated by the highest number of conformations. The best
docking complex solutions (poses) were analyzed according to the potential intermolecular interactions
(ligand/enzyme), such as hydrogen bonding and the cation-pi, pi-pi stacking.
4. Conclusions
This is the first report about the alkaloid profile and biological activities of H. reticulatum.
Twelve alkaloids were identified in this species, eight known and four new, 6α-hydroxymaritidine,
6β-hydroxymaritidine, reticulinine and isoreticulinine. The low cytotoxicity of the epimers
6β-hydroxymaritidine (1) and 6α-hydroxymaritidine (2) and the very good interactions of
isoreticulinine (4) with the active sites of the enzymes AChE and BuChE by molecular docking suggests
that H. reticulatum has high potential as a source of alkaloids with pharmacological activities. Finally,
as the molecular docking results indicate that isoreticulinine alkaloid (4) is a promising molecule in the
treatment of Alzheimer's disease, the synthesis of this compound and its analogues will be undertaken
in future work in our laboratories.
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